Data Support 14 Days On/14 Days Off as Optimal Dosing Schedule; CFT7455 is Well Tolerated with Promising Signs of Anti-Myeloma Activity Completed Monotherapy Dose Escalation Demonstrates Anti-Myeloma Activity and Immunomodulatory Effects to Support CFT7455 in Combination with Novel Multiple Myeloma Agents and as a Monotherapy Maintenance Option CFT7455 in Combination with Dexamethasone Results in IMWG Responses at the First Two Dose Levels Studied in Multi-Refractory Multiple Myeloma Patients Dose Escalation Continues for CFT7455 in Combination with Dexamethasone in Relapsed/Refractory Multiple Myeloma, and as a Monotherapy in non-Hodgkin’s Lymphomas; Complete Phase 1 Dose Escalation Data Expected in 2024 C4T to Host Webcast Today at 4:30 pm ET; Webcast Link Available Here WATERTOWN, Mass., Dec.

数据支持14天休息/14天休息作为最佳给药时间表；CFT7455耐受性良好，具有良好的抗骨髓瘤活性迹象。完成的单药治疗剂量递增显示出抗骨髓瘤活性和免疫调节作用，可支持CFT7455与新型多发性骨髓瘤药物联合使用，并且作为单药治疗维持选择，CFT7455与地塞米松联合使用可在研究的前两个剂量水平产生IMWG反应多发性难治性多发性骨髓瘤患者CFT7455联合地塞米松治疗复发/难治性多发性骨髓瘤的剂量持续增加，并作为非霍奇金淋巴瘤的单一疗法；预计2024年C4T完成第一阶段剂量递增数据，将于美国东部时间今天下午4:30主持网络广播；12月12日，马萨诸塞州沃特敦，这里提供网络广播链接。

12, 2023 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science to develop a new generation of small-molecule medicines and transform how disease is treated, today presented clinical data from the ongoing Phase 1 dose escalation portion of its Phase 1/2 clinical trial of CFT7455, a MonoDAC™ degrader of IKZF1/3, for the potential treatment of multiple myeloma (MM) and non-Hodgkin’s lymphomas (NHL).

122023（环球通讯社）--C4 Therapeutics，Inc.（C4T）（纳斯达克：CCCC），一家临床阶段的生物制药公司，致力于推进靶向蛋白质降解科学，以开发新一代小分子药物并改变疾病的治疗方式，今天提供了CFT7455 1/2期临床试验中正在进行的1期剂量递增部分的临床数据，一个MonoDAC™IKZF1/3的降解物，用于多发性骨髓瘤（MM）和非霍奇金淋巴瘤（NHL）的潜在治疗。

These data include results from CFT7455 as a monotherapy for relapsed/refractory (R/R) MM patients, which has completed dose escalation, and interim results from CFT7455 in combination with dexamethasone for R/R MM patients, which continues to enroll patients. C4T also continues to enroll patients in the Phase 1 dose escalation trial exploring CFT7455 as a monotherapy for NHL patients.

这些数据包括CFT7455作为复发/难治性（R/R）MM患者的单一疗法的结果，其已经完成剂量递增，以及CFT7455与地塞米松联合用于R/R MM患者的中期结果，其继续招募患者。C4T还继续招募患者参加1期剂量递增试验，探索CFT7455作为NHL患者的单一疗法。

“We are excited CFT7455 monotherapy is showing promising signs of anti-myeloma and immu.

“我们很兴奋CFT7455单一疗法显示出抗骨髓瘤和免疫的有希望的迹象。